Greenwich Lifesciences Inc (GLSI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Greenwich Lifesciences Inc stock (GLSI) is currently trading at $25.68. Analyst consensus price target for GLSI is $47.50. WallStSmart rates GLSI as Sell.
- GLSI PE ratio analysis and historical PE chart
- GLSI PS ratio (Price-to-Sales) history and trend
- GLSI intrinsic value — DCF, Graham Number, EPV models
- GLSI stock price prediction 2025 2026 2027 2028 2029 2030
- GLSI fair value vs current price
- GLSI insider transactions and insider buying
- Is GLSI undervalued or overvalued?
- Greenwich Lifesciences Inc financial analysis — revenue, earnings, cash flow
- GLSI Piotroski F-Score and Altman Z-Score
- GLSI analyst price target and Smart Rating
Greenwich Lifesciences Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Greenwich Lifesciences Inc (GLSI) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around return on equity and price/book. Significant fundamental concerns warrant caution or avoidance.
Greenwich Lifesciences Inc (GLSI) Key Strengths (0)
Supporting Valuation Data
Greenwich Lifesciences Inc (GLSI) Areas to Watch (4)
Company is destroying shareholder value
Very expensive at 152.8x book value
Very low institutional interest at 10.79%
Small-cap company with higher risk but more growth potential
Greenwich Lifesciences Inc (GLSI) Detailed Analysis Report
Overall Assessment
This company scores 8/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 0 register as strengths (avg 0/10) while 4 fall into concern territory (avg 2.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Price/Book, Institutional Own.. Some valuation metrics including Price/Book (152.81) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -543.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -543.00% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
GLSI Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
WallStSmart Analysis Synopsis
Data-driven financial summary for Greenwich Lifesciences Inc (GLSI) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Greenwich Lifesciences Inc operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Greenwich Lifesciences Inc.
Bottom Line
Greenwich Lifesciences Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Greenwich Lifesciences Inc(GLSI)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for breast and other HER2 / neu-expressing cancers. The company is headquartered in Stafford, Texas.